newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor types Data featured as an oral presentation at ASCO; Company to host investor event via webcast today at